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Rapport de synthèse 
Shorter time to diagnosis and improved stage at 
presentation in Swiss patients with retinoblastoma treated 
from 1963 to 2004. 
But: 
Le rétinoblastome est la tumeur de l'œil la plus fréquente chez l'enfant. Un diagnostic précoce 
est important pour sauver le globe oculaire et la survie du patient. Le but de notre étude est de 
déterminer l'évolution de l'intervalle diagnostique, c'est-à-dire le délai entre les premiers 
symptômes et la date du diagnostic officiel du rétinoblastome, sur une période de 40 ans en 
Suisse. 
Matériel et méthode : 
Il s'agit d'une étude rétrospective faite sur 139 patients suisses traités pour rétinoblastome 
durant trois différentes périodes: (1) 1963-1983; (2) 1984-1993 ; et (3) 1994-2004. On 
compare certaines caractéristiques : le sexe du patient, la latéralité de la maladie, les premiers 
symptômes, leurs observateurs, l'intervalle diagnostique, l'âge au diagnostic, le stade de la 
maladie, l'histoire familiale. 
Résultats: 
37 patients (26.6%) ont été traités dans la première période; 44 (31.7%) dans la période 2 et 
58 (41.7%) dans la période 3. L'intervalle diagnostique diminue de façon significative de 6.97 
mois dans la période 1 à 3.58 dans la période 2 à 2.25 dans la période 3 pour le total des 
malades. Ceci reste significatif pour les rétinoblastomes unilatéraux. De plus, dans ce même 
groupe, on observe une diminution significative des stades avancés de la maladie, groupe E 
selon Murphree (61.5% dans la période 1 ; 46.7% dans la période 2 et 22.2 % dans la période 
3). 
Lorsque la maladie est bilatérale, les mêmes observations se font de façon un peu moins 
marquée. 
Il n'y a aucun patient diagnostiqué au stade E de la maladie en présence d'une anamnèse 
familiale positive. Leucocorie (48.2%) et strabisme (20.l %) sont les symptômes les plus 
fréquents durant les 3 périodes. Les seuls facteurs qui influencent significativement le risque 
d'avoir un stade E de la maladie sont la durée de l'intervalle diagnostic et la période de 
diagnostic. 
Conclusion : 
On constate un progrès dans le diagnostic du rétinoblastome en Suisse, surtout lors de maladie 
unilatérale. De même, des améliorations sont notées dans la maladie bilatérale mais de façon 
non significative. Il est donc important de mieux enseigner aux médecins à reconnaître les 
symptômes oculaires de la maladie et à référer les patients plus tôt aux spécialistes. 
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OBJECTIVES. Retinoblastoma is the most frequent intraocular malignancy in children. 
Early diagnosis is essential for globe salvage and patient survival. The aim of our 
study was to determine how time to diagnosis of retinoblastoma has evolved over 
a 40-year period in Switzerland. 
METHOD AND PATIENTS. A retrospective study of 139 Swiss patients with retinoblastoma 
was performed comparing 3 periods: (1) 1963-1983; (2) 1984-1993; and (3) 
1994-2004. Factors taken into account were gender, laterality of retinoblastoma, 
age at first symptoms, type and first observer of symptoms, time to diagnosis, age 
at diagnosis, disease stage, and family history. 
RESULTS.Thirty-seven patients (26.6%) were treated in period 1, 44 (31.7%) in 
period 2, and 58 (41.7%) in period 3. Overall, the diagnostic interval decreased in 
a significant way from 6.97 months in period 1 to 3.58 in period 2 and to 2.25 in 
period 3. When looking separately at unilateral and bilateral disease, the decrease 
of the diagnostic intcrval rcmained statistically significant in unilateral retinoblas-
toma; there was also a significant reduction in the number of patients with 
advanced group E disease (Murphree classification) (61.5% in period l, 46.7% in 
period 2, 22.2% in period 3). In bilateral disease, the same observations were made 
to a Jesser extent. However, there were no cases with group E disease in 1 O 
patients with positive family history. Leukocoria (48.2%) and strabismus (20.1 %) 
were the 2 most frequent symptoms throughout the 3 periods. The only factors 
that statistically influenced the chances of having a diagnosis of group E disease 
were the diagnostic interval and period of diagnosis. 
CONCLUSIONS. Progress bas been made in the diagnosis of retinoblastoma in Switzer-
land, notably in unilateral disease. Improvement to a lesser extent bas also been 
observed in bilateral cases but without statistical significance. Greater effort is 
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needed to teach physicians-in-training to recognize the 
importance of ocular symptoms and refer patients ear-
lier. 
RETINOBLASTOMA IS THE most common intraocular malignancy in children. It results from malignant 
transformation of primitive retinal cells, has an inci-
dence of -1 in 14 000 to 1 in 34 000, 1- 3 and may be 
unilateral or bilateral. All bilateral cases and 15 % of the 
unilateral cases are hereditary, but only 3 % to 15 % of 
patients have a positive family history. The disease is so 
rare that a primary care physician is unlikely to see more 
than 1 case of retinoblastoma in his or her career. It is 
crucial, therefore, to educate practitioners in the recog-
nition of the major presenting signs such as leukocoria 
and strabismus, as wcll as the rarer inflammatory symp-
toms.4 The individual signs will depend on tumor size 
and location and are frequently intermittent. This makes 
diagnosis more difficult and dependent on the pediatri-
cian's or general practitioner's ability to recognize the 
significancc of these signs and rcfcr the child to a spe-
cialist, and dependent on the regional screening pro-
gram. 
Retinoblastoma is diagnosed at an average age of 18 
months (more specifically, 9 months for bilateral cases 
and 24 months for unilateral disease). 5 Late diagnosis or 
late referral increases the risk of advanced disease and 
lessens the chances of cure.6•7 Although retinoblastoma 
is diagnoscd later in developing countries,6•8•9 a positive 
family history clearly reduces the time to diagnosis. 10•11 
ln countries with well-developed medical care, infor-
ma lion on the interval betwecn the onsct of first symp-
toms and the time to diagnosis of retinoblastoma is rel-
atively scarce. In Switzerland, access to medical care is 
facilitated, and, since 1960, most patients with retino-
blastoma have been treated at the national reference 
center, which specializes in the treatment of ocular tu-
mors in children and adults. The goal of this study was to 
determine how time to diagnosis of retinoblastoma has 
evolved over a 40-year period in Switzerland. 
PATIENTS AND METHODS 
We conducted a retrospective study on all Swiss resident 
patients who were given a diagnosis of retinoblastoma 
between 1963 and 2004, most of whom were treated at 
the national reference center. Of the 452 patients who 
came from different countries and were treated during 
this period at the Lausanne retinoblastoma clinic, 139 
Swiss patients were included into the study. For those 
patients treated at other Swiss centers, data were com-
pleted with the help of the national childhood cancer 
registry and local pediatric oncologists. Information was 
retrieved from the local database and patients' files and 
included gender, laterality of retinoblastoma, age at first 
symptoms, type of symptoms, the first person to observe 
the symptoms, the interval between first symptoms and 
diagnosis (diagnostic interval [DI]), age at diagnosis, dis-
ease stage, family history of retinoblastoma, and the 
reason for the consultation. 
Tumor stage was determined by the ophthalmologist 
at the initial investigation under general anesthesia. The 
patients' disease stage was evaluated according to the 
Reese-Ellsworth classification system, which is based on 
the possibility of globe preservation by radiotherapy.1 2 
Since the introduction of chemotherapy as the prefer-
ential treatment modality for retinoblastoma 1 O years 
ago, a new classification system has been developed that 
considers the probability of globe preservation by che-
motherapy (Murphree classification13). A classification 
for both classification systems was recorded for all pa-
tients, on a retrospective basis for the earlier cases. The 
latter as well as patients included in the study from other 
centers were reclassified by the Lausanne ophthalmolo-
gists on the basis of fundoscopy findings and/or histol-
ogy. The Murphree classification was chosen for this 
study, and the observation time was divided into 3 pe-
riods: (1) 1963-1983; (2) 1984-1993; and (3) 1994-
. 2004. Patients with retinoma were excluded. 
The t test or 1-way analysis of variance was used to 
compare ;::::2 or more means, respectively. The x2 test for 
independence was used to compare proportions. A lo-
gistic regression on 113 cases with complete observa-
tions was performed to study the simultaneous effect of 
age, gender, laterality, presence of strabismus, presence 
of leukocoria, period of diagnosis, and diagnostic delay 
on the risk of presenting with a Murphree group E 
classification. To allow for a possible difference in the 
role of delay between unilateral and bilateral cases, an 
interaction term was also considered between delay and 
laterality. A term for positive familial history could not 
be fittcd because no patient in that category had a group 
E classification. Ail factors, grouped as shown in Table 1, 
were coded in terms of corresponding binary variables. A 
forward-selection procedure was applied to identify the 
minimum set of variables predicting the stage. The re-
sults are presented in terms of relative risk (as approxi-
matcd by the odds ratio) of group E classification at 
diagnosis, the corresponding 95% confidence interval, 
and P value (Wald's test). Ali P values are from 2-sided 
tests. Analyses were performed with SPSS 13 software 
(SPSS Inc, Chicago, IL). 
RESULTS 
General Data 
Between 1963 and 2004, 452 patients were given a 
diagnosis of and treated for retinoblastoma at the Jules 
Gouin Eye Hospital in Lausanne, 139 of whom were 
Swiss patients. This represents 3 to 4 new cases per year 
in Switzerland and an incidence of 1 in 24 000 live 
births.14 Table 1 shows the patients' characteristics. 
TABLE 1 Patient Characteristics 
Gender 
Male 
Female 
Missing 
laterality 
Unilateral 
Bilateral 
Reason for consultation 
leukocoria 
Slrabisrnus 
Others signs 
Positive family history 
Strabismus and leukocoria 
Nosymptoms 
No information 
First signs' observer 
Parents 
Friends/relatives 
Pediatrician 
Ophthalmologist 
Positive familial history 
Others 
Missing 
Age at diagnosis, mo 
<6 
6.1-12 
12.1-24 
>24 
Murphree classification 
A 
B 
c 
D 
E 
Missing 
Mean diagnostic interval, rno 
<1 
1.1-3 
3.1-6 
>6 
Missing 
Years of diagnosis 
1963-1983 
1984-1993 
1994-2004 
n(%) 
75 (54.0) 
63 (45.3) 
1 (0.7) 
93 (66.9) 
46 (33.1) 
67 (48.2) 
28 (20.1) 
16 (11.5) 
11 (7.9) 
9 (6.5) 
2 (1.4) 
6 (4.3) 
108 (77.7) 
4(2.9) 
3(2.2) 
2 (1.4) 
9 (6.5) 
4 (2.9) 
9 (6.5) 
32 (23.0) 
36 (25.9) 
22 (15.8) 
49 (35.3) 
3 (2.2) 
12 (8.6) 
6 (4.3) 
52 (37.4) 
47 (33.8) 
19 (13.7) 
52 (37.4) 
35 (25.2) 
27 (19.4) 
17 (12.2) 
8(5.B) 
37 (26.6) 
44 (31.7) 
58 (41.7) 
There was a slight male predominance, with 54% boys 
to 46% girls. Two thirds had unilateral (66.9%) and one 
third had bilateral (33.l %) disease. The most common 
presenting signs were leukocoria (48.2%), folJowed by 
strabismus (20.1 %). Only a few patients consulted for 
positive family history (7. 9%). Parents were the first to 
observe disease symptoms in 77.7% of the cases. The age 
at diagnosis was <6 months in 23%, 6.1to12 months in 
25.9%, 12 to 24 months in 15.8%, and >24 months in 
35.3% of the patients. Disease group distribution was as 
follows: group A, 3 of 139 (2.2%); group B, 12 of 139 
(8.6.%); group C, 6 of 139 (4.3%); group D, 52 of 139 
(37.4%); group E, 47 of 139 (33.8%). Group A repre-
sents very localized and Jess advanced disease, and group 
E represents the most advanced disease stage. Patients 
were distributed within the 3 periods as follows: ( l) 
1963-1983, 37 patients (26.6%); (2) 1984-1993, 44 
patients (31.7%); (3) 1994-2004, 58 patients (41.7%). 
Dl, Age at Diagnosis, and Stage of Disease 
Table 2 shows the Dl, age at diagnosis, and Murphree 
group E according to the period. Overall, the mean DI 
decreased from 6.9 months in the first period to 3.5 
months in the second and 2.2 months in the third (P = 
.Oll). This decrease was more significant in unilateral 
disease, with 8.5 months in the first period, 4 months in 
the second period, and 1. 7 months in the third period (P 
= .012). In bilateral disease the DI remained more con-
stant over time, with 4.2 months in the first period, 1.8 
months in the' second period, and 3.1 months in the 
third period. 
The mean age at diagnosis was 21.8 months overall, 
with 21.l months for the first period, 25.3 months for 
the second period, and 19.6 months for the third period. 
Patients with bilateral disease received their diagnosis 
earlier at an overall mean of 11.l months of age, with 
12.8 months in period 1, 8.8 months in period 2, and 
11.0 months in period 3. Patients with unilateral disease 
were given their diagnosis at an overall mean age of 27 .1 
months, corresponding to 26.8 months in period 1, 30.2 
months in period 2, and 24.5 months in period 3. 
The occurrence of advanced group E disease de-
creased over time, from a mean of 60% of patients in 
period 1 to 46.2% in period 2 and 25% in period 3 (P = 
.007). This was notably the case in unilateral retinoblas-
toma; group E classification was recordcd as 61.5% in 
period 1, 46.7% in period 2, and 22.2% in period 3 (P = 
TABLE2 Dl, Age at Dlagnosls, and Disease Group According to Periods 
Unilateral p Bilateral p Total p 
Up 1984-1993 1994 Total Up 1984-1993 1994 Total Up 1984-1993 1994 Total 
to and ta and to and 
1983 After 1983 After 1983 After 
DJ,mo 8.54 4.03 1.74 4.04 .012' 4.25 1.86 3.15 3.16 .335 6.97 3.58 2.25 3.76 .OlP 
Age,mo 26.89 30.22 24.53 27.17 .658 12.82 8.88 11.05 11.16 .601 21.19 25.37 19.65 21.87 .459 
Murphree E, % 61.5 46.70 22.20 38.0 .02' 58.3 44.4 30.0 41.5 .283 60.0 46.2 25.0 39.2 .007" 
·' Stalistically significant results. 
.02). In bilateral disease, the tendency was clearly the 
same but did not rcach statistical significance. 
The influence of gender, age at diagnosis, laterality, 
stage, period of diagnosis, observers, and type of symp-
toms as risk factors for delay in diagnosis was analyzed 
by a logistic-regression analysis. The only factors that 
statistically influenced the chances of being given a di-
agnosis of group E disease were the DI and period of 
diagnosis, which is illustrated in Table 3. 
Positive Family History 
The difference in DI with regard to disease group was 
most obvious among patients with positive family his-
tory (FH+) compared with those with negative family 
history (FH-). Mean age at diagnosis was only 3.6 
months in FH+ families (mean DI: 0 months), whereas 
in FH- children, mean age at diagnosis was 23.5 months 
(mean DI: 4.09 months) (P < .001). In FH+ patients, no 
group E disease was recorded (0 of 10), compared with 
42.5% (45 of 106) in FH- patients. The data are sum-
marized in Table 4. 
DISCUSSION 
It is well known that smaller tumors and less-advanced 
disease stage offer better chances for cure. This is also 
true for retinoblastoma, especially with the progress in 
treatment over the past 20 years. Currently, >90% of 
children with retinoblastoma survive their disease.1·15 In 
recent years, more-conservative eye-sparing treatment 
has enabled children to be cured with Jess morbidity, in 
particular, by avoiding external beam radiation and us-
ing chemotherapy. 16 This strategy, however, is mostly 
successful in less-advanced retinoblastoma, Murphree 
stage A through C or Reese-Ellsworth stage I through Ill, 
as shown in earlier studies. 17·1 8 Advanced stages of dis-
ease continue to require enucleation and/or external 
beam radiotherapy, the latter with increased risks for 
visual impairment, severe cosmetic deformities, and sec-
ondary malignancies. 19·20 Experience from developing 
countries clearly shows that advanced age and delayed 
diagnosis increase the risk of extraocular disease and 
diminish the perspective for cure.21.22 
In Switzerland, access to medical care is facilitated by 
short traveling distances and the obligatory health insur-
TABLE 3 Rlsk for Group E Dlsease ln Relatlonshlp to Perlod and Dl 
Risk of Stage E 95% Confidence lnterval (P) 
PeriocJ 
3: 1994-2004 1.00 
2: 1984-1993 2.50 0.99-6.35 (.053) 
1: 1963-1983 3.62 1.15-11.39 (.028) 
Dl 
<lmo 1.00 
1-3mo 1.41 0.5--4.00 (.518) 
3-6mo 1.77 0.59-5.25 (.306) 
>6mo 8.09 1.86-35.23 (.005) 
TABLE 4 Characteristics of Patients With and Without Positive 
Family History 
Age at diagnosis, mo (P < .001) 
Dl, mo (P < .001) 
Disease's stage, Murphree A-D, % (n) 
Murphree stage E, % (n) (P = .006) 
FH+ 
3.6 
0.00 
100.0 (10) 
0.0(0) 
FH-
23.5 
4.09 
57.5 (61) 
42.5 (45) 
ance system. Access to specialized centers bas also im-
proved during recent years. We were interested, there-
fore, in determining how diagnosis of a rare disease such 
as retinoblastoma has evolved over a 40-year period. 
Our results are consistent with those of other studies 
concerning gender distribution and the proportion of 
patients with unilateral (60%) and bilateral (40%) dis-
ease.5·23 
Similar to previous large studies, we identified leuko-
coria as the most common initial symptom, followed by 
strabismus.24•25 The symptoms did not change over time. 
In nearly 80% (77.7%) of the cases the parents were the 
first to observe an ocular abnonnality in their child.2<• 
This serves as a reminder that parents should be listened 
to carefully when describh1g the symptoms they ob-
served in their children. On the other band, it is worri-
some that only 2.2% of pediatricians detected ocular 
signs first, because checking for a red fundus reflex is 
part of a young child's periodic pediatric examination. 
Age at diagnosis was higher in unilateral (27.1 months) 
than bilateral (11.16 months) retinoblastoma, similar to 
that reported in the literature. Indeed, Goddard et al5 
found a mean age at diagnosis of 9 months for bilateral 
and 24 months for unilateral disease, and Butros et aJ26 
found a mean age of 12.8 months in bilateral and 23.3 
months in unilateral retinoblastoma. As a whole, half of 
our patients were given their diagnosis before the age of 
1 year. It is interesting to note that Wirix et al27 showed 
a difference of age at diagnosis related to the type of 
symptoms. Patients with leukocoria were younger 
(mean age: 20.6 months) at diagnosis than patients with 
strabismus (mean: 32 months). This is not surprising, 
because strabismus would normally develop only when 
central vision is impaired by a macular tumor that is 
most often unique, in contrast to any peripheral, often 
multifocal tumor location that can cause leukocoria, 
which is easier to detect by the family. In our study, no 
relationship was found between the type of symptoms 
and age at diagnosis or laterality. 
As shown in Table 2, the main finding in our patients 
was the reduction in the DI over time (P = .011). When 
the series was stratified according to laterality, this re-
duction remained statistically significant in patients with 
unilateral retinoblastoma. but showed 01ùy a trend in 
bilateral disease, although the latter started with a 
shorter DI already in the first period. Age at diagnosis, 
however, remained unchanged, as did the symptoms. It 
might have been expected that a better recognition of 
symptoms would reduce the DI in both bilateral and 
unilateral cases, with leukocoria being the main symp-
tom in both patient groups. A concomitant increase of 
strabismus as the main symptom in bilateral retinoblas-
toma could be a plausible explanation, because "malig-
nant" strabismus is always more difficult to recognize 
and differentiate from "banal" strabismus, whereas leu-
kocoria, once detected, is always alarming. The retro-
spective nature of our study limits the conclusions that 
can be drawn, with insufficient information on the spe-
cific time to reaction or Dls by the parents, pediatrician, 
general practitioner, or ophthalmologist. We hypothe-
size that leukocoria in older children with unilateral 
retinoblastoma is recognized more rapidly and incites 
parents to consult the doctor, whereas younger children 
with bilateral retinoblastoma might experience a period 
of strabismus that goes unnoticed until the development 
of leukocoria alerts the parents to seek medical atten-
tion. Franzco et al23 found earlier diagnosis over time in 
bilateral retinoblastoma in a review of 165 patients over 
a 50-year period (divided into 3 parts). They explained 
this by a higher proportion of positive family history in 
bilateral retinoblastoma in the more recent time period, 
increasing the proportion of systematically screened 
children. They could not confirm this hypothesis statis-
tically. 
The majority of our patients (82%) were given their 
diagnosis within 6 months from the first symptoms. This 
is shorter than the mean overall lag time of 8.3 months 
reported by Erwenne and Franco,21 who found that 
47.7% of their patients had a DI of >6 months. The time 
limit of 6 months is an important factor, because diag-
nosis of bilateral retinoblastoma beyond 4 months seems 
to correlate with greater risk of blindness28 and compro-
mises salvage treatment.26 
The other important observation in our study is the 
progressively smaller number of patients who present 
with group E disease, notably in unilateral and with a 
clear tendency in bilateral disease (Table 2). Group E, the 
most advanced disease stage, is rarely curable by conser-
vative treatment, with most cases requiring enucleation 
or radiotherapy. To discard the possibility of retrospec-
tive Murphree staging influencing the larger number of 
group E classifications in the early period, we checked 
group D disease, which showed complete stability 
throughout the observation periods, which supports a 
real decrease in group E disease. Another factor is the 
absence of group E disease in a small number of patients 
who were screened and given a diagnosis early on the 
basis of positive family history (Table 4). Ali these pa-
tients have been treated by local treatment alone or in 
combination with chemoreduction. Other authors also 
showed that early detection allows local intraocular 
treatment of small tumors with a much better chance of 
globe preservation and visual function. In a review of 
250 patients, Haik et al29 demonstrated that in patients 
with positive family history, the time of firsl symptoms 
to diagnosis was 2 weeks to 5 months (mean age at 
diagnosis: 6 months), in contrast to patients with nega-
tive family history, who showed a thne of first symptoms 
to diagnosis of 2 weeks to 57 months (mean age at 
diagnosis: 19 months). Abramson et al24 demonstrated a 
mean age at diagnosis of 10.8 months if there was pos-
itive family history and 7.7 months if both positive fam-
ily history and screening were combined. Mollet al 11 also 
established that screening reduces the age at diagnosis 
and recommended that it be repeated up to the age of 4 
years, because some families remain unaware of the risk 
of recurrence of retinoblastoma despite ail explanations 
given. This corresponds to our own procedure of com-
bining genetic counseling with intrauterine ultrasound 
monitoring of pregnancies at risk for retinoblastoma and 
screening from birth until 10 years of age (Table 5). 
CONCLUSIONS 
We conclude that progress has been made in the diag-
nosis of retinoblastoma in Switzerland, notably in uni-
lateral disease, with a reduction in both the DI and 
number of cases presenting with advanced-stage disease. 
The figures for bilateral cases have remained more con-
stant, which leaves room for improvement in a disease 
that may be extensive in young children, compronùsing 
not only visual function but also globe salvage and even 
survival. It is our hypothesis that with the earlier age of 
onset in bilateral cases, strabismus in very young infants 
is common and an underlying disease Jess likely to be 
suspected than in the presence of leukocoria. It must be 
stressed to physicians-in-training that looking for a red 
fundus reflex must be part or every pediatric examina-
tion in young children and that strabismus denotes an 
obligation to refer the child to a general ophthalmologist 
for a first evaluation, after which the specialized team 
will be consulted as necessary. Swiss pediatric guidelines 
currently recommend the referral of patients to the oph-
thalmologist for any strabismus present at ;:::4 months or 
TABLE 5 Recommendatlon for Screenlng of Patients With Positive 
Family History 
Rlsk of Genetie Transmission 
50%-100% Offspring from parents 
with bilateral hereditary 
retinoblastoma 
-10% Siblings of patients with 
sporadic bilat~ral 
retinoblastoma 
-1 % Siblings of patients with 
sporadic unilateral 
retinoblastoma 
Ophthalmologlc Examlnatlon 
Birth and at 1, 2, 3, 4, 6, 8, 10, 12, 15, 18, 21, 
24, 28, 32, 36, 42, and 48 rno, under 
ge11e1al anesthesia; after 48 rno, annual 
contrai until 10 y of age without 
anesthesia 
Birth and 1, 3, 6, 10, 15, 21, 28, 36, and 42 
mo, under general anesthesia; after 48 
rno, annual control until 10 y of age 
without anesthesia 
Birth and every 6 mo until 48 mo without 
anesthesia 
at a younger age in the case of persistent strabismus. 
Given the risk of rapid disease progression in infants, it is 
our opinion that referral of the patient after 1 month of 
age in cases of doubtful or persistent strabismus would 
be more appropriate. 
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